KR20250166964A - 아즈부딘을 포함한 항종양 약학적 조성물 - Google Patents

아즈부딘을 포함한 항종양 약학적 조성물

Info

Publication number
KR20250166964A
KR20250166964A KR1020257033469A KR20257033469A KR20250166964A KR 20250166964 A KR20250166964 A KR 20250166964A KR 1020257033469 A KR1020257033469 A KR 1020257033469A KR 20257033469 A KR20257033469 A KR 20257033469A KR 20250166964 A KR20250166964 A KR 20250166964A
Authority
KR
South Korea
Prior art keywords
cancer
tumor
pharmaceutical composition
egfr
azbudine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257033469A
Other languages
English (en)
Korean (ko)
Inventor
판 리
리민 지아
지용 친
조양 왕
Original Assignee
허난 제뉴인 바이오테크 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허난 제뉴인 바이오테크 컴퍼니 리미티드 filed Critical 허난 제뉴인 바이오테크 컴퍼니 리미티드
Publication of KR20250166964A publication Critical patent/KR20250166964A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257033469A 2023-03-03 2024-03-01 아즈부딘을 포함한 항종양 약학적 조성물 Pending KR20250166964A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202310201580.X 2023-03-03
CN202310201580.XA CN116212030A (zh) 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物
PCT/CN2024/079625 WO2024183644A1 (zh) 2023-03-03 2024-03-01 包含阿兹夫定的抗肿瘤药物组合物

Publications (1)

Publication Number Publication Date
KR20250166964A true KR20250166964A (ko) 2025-11-28

Family

ID=86468723

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257033469A Pending KR20250166964A (ko) 2023-03-03 2024-03-01 아즈부딘을 포함한 항종양 약학적 조성물

Country Status (7)

Country Link
US (1) US11878028B1 (https=)
EP (1) EP4424310B1 (https=)
JP (1) JP7783217B2 (https=)
KR (1) KR20250166964A (https=)
CN (1) CN116212030A (https=)
TW (1) TW202435855A (https=)
WO (1) WO2024183644A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物
CN116196325A (zh) * 2023-03-10 2023-06-02 河南真实生物科技有限公司 包含阿兹夫定的免疫调节剂组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
CN102000103B (zh) * 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
CN113171350B (zh) * 2015-06-03 2023-05-26 南京三迭纪医药科技有限公司 药品剂型及其使用
CN109562176A (zh) * 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
TWI818007B (zh) * 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI762784B (zh) * 2018-05-23 2022-05-01 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
EP3954682A4 (en) * 2019-04-09 2022-10-12 Henan Genuine Biotech Co., Ltd. 2-(2,4,5-substituted phenylamino)pyrimidine derivative and crystal form b thereof
CN110003183A (zh) * 2019-04-09 2019-07-12 河南真实生物科技有限公司 2-（2，4，5-取代苯氨基）嘧啶衍生物及其晶形b
JP2023510426A (ja) * 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
CN114191558A (zh) * 2020-09-17 2022-03-18 上海翰森生物医药科技有限公司 Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
CN114569728B (zh) * 2020-11-30 2023-11-28 诺未科技（北京）有限公司 一种组合物及其应用和药物
CN115006397A (zh) * 2021-03-05 2022-09-06 上海翰森生物医药科技有限公司 一种预防或治疗肿瘤疾病的药物用途
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Also Published As

Publication number Publication date
JP7783217B2 (ja) 2025-12-09
CN116212030A (zh) 2023-06-06
EP4424310A1 (en) 2024-09-04
JP2024125139A (ja) 2024-09-13
WO2024183644A1 (zh) 2024-09-12
EP4424310C0 (en) 2025-07-16
US11878028B1 (en) 2024-01-23
EP4424310B1 (en) 2025-07-16
TW202435855A (zh) 2024-09-16

Similar Documents

Publication Publication Date Title
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2587013C2 (ru) Комбинированная химиотерапия
KR20250166964A (ko) 아즈부딘을 포함한 항종양 약학적 조성물
TWI754170B (zh) Ｊａｋ激酶抑制劑與ｅｇｆｒ抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
WO2015015013A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
KR20250167640A (ko) 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물
KR20210068344A (ko) 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2019002542A1 (en) COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
EP2754441B1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
MX2015006592A (es) Terapia de combinacion con volasertib.
WO2022057812A1 (zh) 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
US20220323470A1 (en) Composition and use thereof in the manufacture of medicament for treating cancer
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
US11179349B2 (en) Use of tumor gene methylation regulator and anti-tumor drugs
CN113679720B (zh) 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途
KR20250088371A (ko) Ezh2 저해제 및 jak3 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
CN119326894A (zh) Gsdme抑制剂用于制造预防和治疗化疗时外周神经损伤的药物的用途
CN114569619A (zh) Pi3k抑制剂单用或联合egfr抑制剂在制备治疗头颈癌或胃癌的药物中的用途
CA3198190A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
HK40049617A (en) Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent
CN111544580A (zh) 一种抗癌症的药物组合物
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
US20140235581A1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
HK1227400B (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)